Provided by Tiger Trade Technology Pte. Ltd.

TEMA ONCOLOGY ETF

41.53
-0.2349-0.56%
Post-market: 41.47-0.0585-0.14%19:30 EDT
Volume:28.72K
Turnover:1.20M
Market Cap:203.90M
PE:- -
High:42.30
Open:42.30
Low:41.47
Close:41.76
52wk High:47.00
52wk Low:26.62
Shares:4.91M
Float Shares:4.91M
Volume Ratio:1.14
T/O Rate:0.58%
Dividend:0.02
Dividend Rate:0.05%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley

TIPRANKS
·
Aug 28

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Aug 28

FDA Approves Lilly's Mounjaro to Cut Cardiovascular Event Risk in High-Risk Type 2 Diabetes Adults

Reuters
·
Aug 28

FDA Approves Lilly's Mounjaro (Tirzepatide) to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes

THOMSON REUTERS
·
Aug 28

US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech

Deep News
·
Aug 28

Dow Jones Top Company Headlines at 11 PM ET: Judge Rules Trump Administration's Blacklisting of Anthropic was Unlawful | Nvidia ...

Dow Jones
·
Aug 28

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Dow Jones
·
Aug 28

Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says

MT Newswires Live
·
Aug 28

Eli Lilly (LLY) Says Zepbound Cuts Healthcare Costs For Adults Over 55

Simply Wall St.
·
Aug 27

Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era

Reuters
·
Aug 27

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)

TIPRANKS
·
Aug 27

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230

THOMSON REUTERS
·
Aug 27

Eli Lilly & Co. Stock Slips 3.6%, Underperforms Peers

Dow Jones
·
Aug 27

Sector Update: Healthcare

MT Newswires Live
·
Aug 27

Roche receives FDA approval for companion diagnostic tests for Ziihera

TIPRANKS
·
Aug 27

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

MT Newswires Live
·
Aug 27

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live
·
Aug 27

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS
·
Aug 27

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Reuters
·
Aug 27

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

TIPRANKS
·
Aug 27